Notable Labs Ltd. (NTBL)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now
Notable Labs (NTBL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Notable Labs Ltd. (NTBL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Notable Labs Ltd. ever had a stock split?
Notable Labs Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Kaile Zagger CEO | NASDAQ (CM) Exchange | IL0012002452 ISIN |
| IL Country | 16 Employees | - Last Dividend | 17 Oct 2023 Last Split | 17 Oct 2023 IPO Date |
Overview
Notable Labs, Ltd. is a forward-looking biotechnology firm founded in 2014, focusing on the development of predictive precision medicines aimed at combating cancer. The company is dedicated to revolutionizing cancer treatment through its proprietary Predictive Precision Medicines Platform (PPMP). This innovative platform offers a bio-simulation of cancer treatments, providing predictions on patient responses to their actual treatment regimens. Based in Foster City, California, Notable Labs, Ltd. is pioneering the approach of selecting clinically responsive patients ahead of treatment, which has the potential to significantly accelerate therapeutic development for those patients.
Products and Services
The company’s dedication to transforming cancer treatment is evident through its development of promising therapies and technologies:
-
Volasertib:
As a potent inhibitor of Polo-like kinase 1 (PLK-1), Volasertib is at the forefront of Notable Labs' innovative pipeline. It's designed to induce cell cycle arrest and apoptosis in various cancer cells, showing promise in the fight against cancer by targeting one of the key regulators of cell division.
-
Fosciclopirox:
A pro-drug of ciclopirox, Fosciclopirox is being developed specifically for the treatment of acute myeloid leukemia (AML). This compound represents Notable Labs' strive towards providing targeted, effective treatments for some of the most challenging types of cancer. The ambition behind Fosciclopirox shows the company’s commitment to expanding its range of cancer therapies, aiming to meet the urgent needs of patients suffering from AML.
